Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 77Neoplasm Metastasis 8Neoplasms 6Prostatic Neoplasms, Castration-Resistant 5Carcinoma, Non-Small-Cell Lung 4Metastatic Castration-Resistant Prostate Cancer 3Colorectal Neoplasms 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Castration-resistant Prostate Cancer 2Carcinoma, Hepatocellular 2Bulbo-Spinal Atrophy, X-Linked 2Breast Neoplasms 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumours 1Salivary Gland Neoplasms 1Prostatic Diseases 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostate Cancer Metastatic Disease × abiraterone × Clear all
NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
192 enrolled
Genitourinary

Prostate Cancer Metastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡